Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | YAP1 | P46937 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24940830 | 0.90 | MEN1 (0.43) | P2RX7MEN1KMT2ABACE1TACR1 | |
| SCHEMBL1950941 | 0.89 | P2RX7 (0.41) | P2RX7MEN1KMT2ABACE1STS | |
| SCHEMBL16825735 | 0.88 | MEN1 (0.45) | P2RX7MEN1KMT2ABACE1TACR1 | |
| SCHEMBL27139196 | 0.87 | OPRD1 (0.43) | P2RX7MEN1KMT2ABACE1TACR1 | |
| SCHEMBL30732662 | 0.87 | MEN1 (0.42) | P2RX7MEN1KMT2ABACE1TACR1 | |
| SCHEMBL743654 | 0.87 | TACR1 (0.43) | P2RX7MEN1KMT2ABACE1TACR1 | |
| SCHEMBL607180 | 0.86 | MEN1 (0.46) | P2RX7MEN1KMT2ABACE1TACR1 | |
| SCHEMBL4780268 | 0.85 | NPFFR1 (0.48) | P2RX7MEN1KMT2ABACE1TACR1 | |
| SCHEMBL4780264 | 0.85 | NPFFR1 (0.48) | P2RX7MEN1KMT2ABACE1TACR1 | |
| SCHEMBL5721029 | 0.85 | BACE1 (0.42) | P2RX7MEN1KMT2ABACE1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485647-B2 | 2-aminoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-03 | — | — | US | disclosed |
| US-20060287340-A1 | 2-Aminoquinoline derivatives | MSD K.K. (JP) | 2006-12-21 | — | — | US | disclosed |
| EP-1630162-A1 | 2-AMINOQUINOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287340-A1 | 2-Aminoquinoline derivatives | MCHR2, MC2R, MCHR1 | P2RX7 379/4885MEN1 910/4885KMT2A 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.